Well, the long-awaited final action letter from DEA has arrived. AIMS Institute is now clear to pursue its claims against DEA to stop DEA from interdicting use of Phase II experimental psilocybin compounds on terminally ill cancer patients under Federal Right to Try law. This has been an ongoing saga of the clinic, its doctors’ and its patients’ efforts to secure consent to use the compound as part of their personal palliative care. The path has been mired with administrative and procedural obstacles that already placed the case on an Odessey from trial court to appellate court and back again. With DEA’s issuance of its final action letter, the path is now clear.
Come read the letter HERE.